Bachmann Paula, Frahm Niklas, Debus Jane Louisa, Mashhadiakbar Pegah, Langhorst Silvan Elias, Streckenbach Barbara, Baldt Julia, Heidler Felicita, Hecker Michael, Zettl Uwe Klaus
Section of Neuroimmunology, Department of Neurology, Rostock University Medical Center, Gehlsheimer Str. 20, 18147 Rostock, Germany.
Ecumenic Hainich Hospital Mühlhausen, Pfafferode 102, 99974 Mühlhausen, Germany.
Pharmaceutics. 2022 Mar 8;14(3):592. doi: 10.3390/pharmaceutics14030592.
Polypharmacy (PP) is a common problem in modern medicine, especially known to affect patients with chronic diseases such as multiple sclerosis (MS). With an increasing number of drugs taken, the risk of potential drug-drug interactions (pDDIs) is rising. This study aims to assess the prevalence and clinical relevance of polypharmacy and pDDIs in patients with MS. Pharmacological data of 627 patients with MS were entered into two drug-drug-interaction databases to determine the number and severity of pDDIs for each patient. The patients were divided into those with and without PP (total PP and prescription medication PP (Rx PP)). Of the 627 patients included, 53.3% and 38.6% had total PP and Rx PP, respectively. On average, every patient took 5.3 drugs. Of all patients, 63.8% had at least one pDDI with a mean of 4.6 pDDIs per patient. Less than 4% of all pDDIs were moderately severe or severe. Medication schedules should be checked for inappropriate medication and for possible interacting drugs to prevent pDDIs. Physicians as well as pharmacists should be more sensitive towards the relevance of pDDIs and know how they can be detected and avoided.
多重用药（PP）是现代医学中一个常见问题，尤其在影响患有慢性疾病（如多发性硬化症（MS））的患者方面广为人知。随着所服用药物数量的增加，潜在药物相互作用（pDDI）的风险也在上升。本研究旨在评估MS患者中多重用药和pDDI的患病率及临床相关性。将627例MS患者的药理学数据录入两个药物相互作用数据库，以确定每位患者pDDI的数量和严重程度。这些患者被分为有和没有PP的两组（总体PP和处方药物PP（Rx PP））。在纳入的627例患者中，分别有53.3%和38.6%患有总体PP和Rx PP。平均而言，每位患者服用5.3种药物。在所有患者中，63.8%至少有1种pDDI，每位患者平均有4.6种pDDI。所有pDDI中，中度严重或严重的不到4%。应检查用药计划中是否存在不适当用药和可能相互作用的药物，以预防pDDI。医生和药剂师都应对pDDI的相关性更加敏感，并了解如何检测和避免它们。
